Table 3.
Volunteers with local and systemic solicited adverse events within 7 days of product administration
|
Group A (n=3) |
Group B (n=3) |
Group C (n=3) |
Group D (n=3) |
Group D1 (n=4) |
Placebo (n=5) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mild | Moderate | Mild | Moderate | Mild | Moderate | Mild | Moderate | Mild | Moderate | Mild | Moderate | |
| Pain | 0 | 0 | 1 (33%) | 1 (33%) | 1 (33%) | 1 (33%) | 1 (33%) | 2 (67%) | 2 (50%) | 1 (25%) | 2 (40%) | 0 |
| Tenderness | 2 (67%) | 0 | 3 (100%) | 0 | 2 (67%) | 1 (33%) | 1 (33%) | 2 (67%) | 2 (50%) | 0 | 2 (40%) | 0 |
| Chills | 0 | 0 | 0 | 0 | 1 (33%) | 0 | 1 (33%) | 0 | 1 (25%) | 0 | 0 | 0 |
| Malaise | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (67%) | 2 (50%) | 1 (25%) | 0 | 0 |
| Myalgia | 0 | 0 | 0 | 0 | 1 (33%) | 1 (33%) | 1 (33%) | 1 (33%) | 2 (50%) | 1 (25%) | 1 (20%) | 0 |
| Headache | 1 (33%) | 0 | 2 (67%) | 0 | 1 (33%) | 0 | 2 (67%) | 1 (33%) | 2 (50%) | 1 (25%) | 2 (40%) | 0 |
| Nausea | 0 | 0 | 0 | 0 | 0 | 0 | 1 (33%) | 0 | 1 (25%) | 0 | 0 | 0 |
Data are n (%). No vomiting, fever, erythema, or induration adverse events were reported.